Efficacy and Safety of Turoctocog Alfa for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Chinese Patients With Haemophilia A

Trial Profile

Efficacy and Safety of Turoctocog Alfa for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Chinese Patients With Haemophilia A

Recruiting
Phase of Trial: Phase III

Latest Information Update: 04 Sep 2017

At a glance

  • Drugs Turoctocog alfa (Primary)
  • Indications Haemophilia A
  • Focus Therapeutic Use
  • Acronyms guardian TM 7
  • Sponsors Novo Nordisk
  • Most Recent Events

    • 17 Feb 2017 Planned End Date changed from 1 Dec 2018 to 14 Dec 2018.
    • 17 Feb 2017 Planned primary completion date changed from 1 Dec 2018 to 14 Dec 2018.
    • 16 Dec 2016 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top